Ncardia has launched a human-derived microglia cell model, called Ncyte Microglia, that the company says may help advance research in Parkinson’s disease and other neurodegenerative conditions — and which may be a tool in the development of new therapies. Microglia are resident immune cells in the brain that…
The European Medicines Agency (EMA), which evaluates the safety and efficacy of new drugs in the European Union, has waived a requirement that would have had Irlab Therapeutics conducting clinical trials testing mesdopetam — its therapy candidate for levodopa-induced dyskinesia, or uncontrolled, involuntary movements common in Parkinson’s disease…
Parkinson’s disease research and care should address disparities by sex and gender in patients’ symptoms, treatment responses, and disease progression, scientists across Europe and North America state in a commentary. While sex refers to assigned biological differences between males and females, gender refers to how a person identifies, affecting…
A nanoparticle-based wireless deep brain stimulation (DBS) system restored the activity of degenerating neurons and increased dopamine release in cellular and mouse models of Parkinson’s disease, a study shows. The technology also eliminated alpha-synuclein clumps, a hallmark feature of the disease, and improved the animals’ motor abilities. According…
Hearing loss may be a risk factor for developing Parkinson’s disease, or may be an early warning sign of the neurodegenerative condition, according to a new study from the U.K. Specifically, the study found that for every 10 decibels of hearing impairment, the risk of developing Parkinson’s increased by…
The Michael J. Fox Foundation (MJFF) has launched this year’s “Parkinson’s IQ + You,” a series of in-person events to help patients and care partners effectively navigate the challenges of Parkinson’s disease. Launched in 2019, the free event series seeks to educate people about the disease, including…
A Phase 2 clinical trial of AB-1005, AskBio’s gene therapy for Parkinson’s disease, has randomly assigned its first participants to different treatment groups, the company has announced. Called REGENERATE-PD (NCT06285643), the trial is expected to enroll about 87 adults with moderate Parkinson’s, ages 45 to 75, who…
Medtronic’s BrainSense adaptive deep brain stimulation (aDBS) system and electrode identifier have received CE Mark approval in the European Union (EU) and the U.K. for the management of Parkinson’s disease. CE Mark approval indicates that the European Commission, the EU’s regulatory body, considered Medtronic’s system to meet…
A research project that’s designed to help improve communication for people with Parkinson’s disease by focusing on listener training has been awarded a $2.6 million, five-year grant from the National Institutes of Health (NIH). The funding will help researchers implement a structured listener training program and test its effectiveness in…
Mytos and Aspen Neuroscience are teaming up to automate the manufacture of autologous dopaminergic neuronal precursor cells (DNPCs) for ANPD001, Aspen’s experimental cell therapy program for Parkinson’s disease. As part of the agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing…
Get regular updates to your inbox.
